Published Date: Thu, Nov 19, 2026 NEW
For members with our Anti-Obesity Enhanced pharmacy benefit, the Zepbound single-dose pen will no longer be a preferred medication, starting Jan. 1, 2027, and upon authorization renewal.
Instead, the following drugs will be preferred:
Both members and their prescribers will be notified of these changes via letter starting in late November.
Members currently authorized for the Zepbound single-dose pen will also be authorized for Zepbound Kwikpen, Wegovy injection, and Wegovy oral tablet by Jan. 1, 2027. The authorization will start on Jan. 1, 2027, and end at the same time as their current Zepbound single-dose pen authorization. This allows members to access these medications without needing to submit another authorization.
Important: Members requesting Zepbound Kwikpen will need to try and fail both Wegovy AND Zepbound Kwikpen.
Write a new prescription if your patient is changing from Zepbound single-dose pen to one of the preferred medications listed above. Zepbound Kwikpen also requires a prescription for compatible pen needles.
This policy change does not impact members with the Anti-Obesity Standard pharmacy benefit, subject to pharmacy policy J-1389.
Highmark regularly evaluates its prescription medication policies, including those for weight loss. We are focused on prioritizing the most clinically effective and cost-efficient weight loss medications for members, especially those with severe obesity and other obesity-related comorbidities.
Quick Info
Never miss out on what matters. Subscribe to our emails and stay informed.